Comparison of NAFLD , MAFLD and MASLD characteristics and mortality outcomes in United States adults
Liver International · 2024-04 · 44 (4) · 1051-1060
DOI: 10.1111/liv.15856 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 31.01.2024. Verfasst von Rui Song und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Metabolic Diseases. Die Arbeit wurde bisher 107-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: the First Batch of Key Disciplines on Public Health in Chongqing.
Abstract (Originalsprache)
Background & Aims Following the classification of metabolic dysfunction‐associated fatty liver disease (MAFLD), non‐alcoholic fatty liver disease (NAFLD) has recently been redefined again as metabolic dysfunction‐associated steatotic liver disease (MASLD). However, the distinctions in characteristics and mortality outcomes between NAFLD, MAFLD and MASLD remain unclear.
Methods
We analysed data from 7519 participants in the third National Health and Nutrition Examination Surveys of United States (US) and their linked mortality until 2019. Survey weight‐adjusted multivariable Cox proportional model was used to study the mortality over three terms.
Results
The prevalence of NAFLD, MAFLD and MASLD was 18.5%, 19.3% and 20.8%, respectively. Most individuals with NAFLD (94.5%) or MAFLD (100%) can be classified as MASLD, while a relatively low percentage of those with MASLD were also diagnosed with either NAFLD (84.1%) or MAFLD (92.7%). During a median follow‐up of 26.9 years, both MAFLD and MASLD were associated with increased risk of all‐cause mortality (adjusted hazard ratio [aHR] 1.18, 95% CI 1.04–1.33 and 1.19, 1.06–1.34, respectively), this association was mainly observed in NAFLD−/MASLD+ subgroups. NAFLD was not associated with all‐cause mortality. However, all three terms were associated with an increased risk of all‐cause mortality in individuals with advanced fibrosis (aHR: 1.71–1.81). Subgroup analyses showed that higher risk of all‐cause mortality for both MAFLD and MASLD were observed among older adults (≥65 year), non‐Hispanic whites and those without diabetes.
Conclusions
Both MASLD and MALFD were linked to higher all‐cause mortality risk, but MASLD identified a greater number of individuals compared to MAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chon…
- Department of Gastroenterology, The Seventh People's Hospital of Chongqing, Chongqing, China.
- Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
ORCID-Profile: Zhiwei Chen
Förderung
- the First Batch of Key Disciplines on Public Health in Chongqing
Zitieren
APA
Song, R., Li, Z., Zhang, Y., Tan, J., & Chen, Z. (2024). Comparison of NAFLD , MAFLD and MASLD characteristics and mortality outcomes in United States adults. Liver International, 44(4), 1051-1060. https://doi.org/10.1111/liv.15856
Vancouver
Song R, Li Z, Zhang Y, Tan J, Chen Z. Comparison of NAFLD , MAFLD and MASLD characteristics and mortality outcomes in United States adults. Liver International. 2024;44(4):1051-1060. doi:10.1111/liv.15856
BibTeX
@article{Song2024,
author = {Song, Rui and Li, Zhao and Zhang, Yingzhi and Tan, Jiahe and Chen, Zhiwei},
title = {Comparison of NAFLD , MAFLD and MASLD characteristics and mortality outcomes in United States adults},
journal = {Liver International},
year = {2024},
volume = {44},
number = {4},
pages = {1051--1060},
doi = {10.1111/liv.15856}
}
EUVIMED